CDBN-YGXZ显示出对Clostridioides difficile的高度抗菌活性,作为一种潜在的候选药物
Xiaoxia Zhang1, Min Quan1, Xin Lu1
1Centre of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
CDBN-YGXZ对Clostridioides difficile表现出强大的抗菌活性,有效抑制细菌粘附并显示出耐药性发展的低潜力. 这种化合物是治疗药物开发的有希望的候选者.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 艰难菌感染 (CDI) 是一个重要的医疗保健挑战,通常与抗生素耐药性有关.
- 需要新的治疗药物来对抗持久性和复发性CDI.
研究的目的:
- 评估CDBN-YGXZ对Clostridioides difficile的临床分离物的体外抗菌活性.
- 评估CDBN-YGXZ在抑制C. difficile粘附于肠道细胞方面的潜力及其诱导细菌耐药性的倾向.
主要方法:
- 对各种临床Clostridioides difficile菌株的最小抑制度 (MIC) 确定.
- 对CDBN-YGXZ对C. difficile粘附于Caco-2肠上皮细胞的影响的评估.
- 评估CDBN-YGXZ诱导细菌耐药性的潜力.
主要成果:
- CDBN-YGXZ对临床C. difficile菌株的MIC范围较低 (0.0150.125 mg/L).
- 该化合物显著抑制了86.2%的C. difficile粘附于Caco-2细胞.
- CDBN-YGXZ证明了细菌耐药性的诱导最小.
结论:
- CDBN-YGXZ具有强大的抗菌活性,可以对抗Clostridioides difficile.
- 它抑制细菌粘附的能力和低抗性潜力使其成为CDI治疗开发的有希望的候选人.
更多相关视频
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
相关概念视频
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antibiotic Selection
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
